Lecithin–cholesterol acyltransferase (LCAT) activity is lower in patients with type 2 diabetes in the presence of metabolic syndrome

Authors

  • Manouchehr Nakhjavani Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
  • Armin Rajab Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
  • Soghra Rabizadeh Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
  • Masoume Bitaraf Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
  • Azam Ghanei Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  • Alireza Esteghamati Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
  • Hossein Mirmiranpour Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran

DOI:

https://doi.org/10.31989/bchd.v3i4.690

Abstract

Backgrounds: Metabolic syndrome can facilitate the development of diabetes mellitus and has gained a negative reputation for its adverse effects on the general health of the population and its tendency to increase the risk of cardiovascular diseases. Cardiovascular complications may be mediated by the alteration of certain enzyme activities and pathways. Lecithin-Cholesterol Acyltransferase (LCAT) may have a potential role in the prevention of atherosclerosis as a rate-limiting enzyme in reverse cholesterol transport. In this study, LCAT activity was compared among patients with type 2 diabetes in the presence or absence of metabolic syndrome.

Methods: In the present study, 55 patients with type 2 diabetes with metabolic syndrome (DM+MS group), 25 patients with type 2 diabetes without metabolic syndrome (DM-MS group),  and a control group of 43 subjects without type 2 diabetes (HC group) were compared based on their anthropometric parameters, lipid profiles, glycemic indices, and LCAT activity.

Results: LCAT activity was lower among participants of the DM+MS group (70.22±7.88) in comparison with the both HC group (89.51±3.59) and the DM-MS group (76.73±7.25) (respectively P<0.001, P=0.021). There was no significant difference in the fasting blood glucose levels, as evidenced by the HbA1c and HOMA-IR measurements between the DM+MS group and the DM-MS group. BMI was significantly higher in the DM+MS group compared to the DM-MS group (P=0.031). In patients with type 2 diabetes mellitus and metabolic syndrome, there was a negative correlation between LCAT activity and BMI (r=-0.275, P=0.048). There was also a negative correlation between LCAT activity and HbA1c in the DM-MS group (r=-0.606, P=0.008) and the DM+MS group (r=-0.421, P=0.002).

Conclusion: LCAT activity was lower among patients with type 2 diabetes compared to subjects without type 2 diabetes and it had a greater reduction in the presence of metabolic syndrome. LCAT activity also had a negative correlation with BMI in patients with type 2 diabetes mellitus and metabolic syndrome compared to patients with type 2 diabetes that did not have metabolic syndrome.

Keywords: Lecithin-Cholesterol Acyltransferase (LCAT), Metabolic syndrome, Diabetes mellitus, type 2, BMI

Downloads

Published

2020-04-30

Issue

Vol. 3 No. 4 (2020): April 2020

Section

Research Articles

License

Any manuscripts or substantial parts of it, submitted to the journal must not be under consideration by or previously published in any other journal or citable form. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights or the rights of a third party. In submitting one's article in any form, the author has assigned the FFC publishing rights and has agreed to an automatic transfer of the copyright to the publisher. This is so that the FFC may create print option journals, for example, at the FFC’s discretion. If the author wishes to distribute their works by means outside of the FFC, for example within their community, they will have to place a request. 

 

Correspondence concerning articles published in Functional Foods in Health and Disease is encouraged. While derivative works (adaptations, extensions on the current work, etc.) are allowed, distribution of the modified material is not allowed without permission from the FFC.